Condition: Alzheimer Disease · Sponsor: Vaccinex Inc.
To investigate safety, tolerability, the effects on cognition and brain metabolism of pepinemab in early AD dementia (early AD) subjects.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Pacific Research Network, Inc | San Diego, California, United States | — |
| Georgetown University | Washington D.C., District of Columbia, United States | — |
| Brain Matters Research | Delray Beach, Florida, United States | — |
| Neuropsychiatric Research Center of Southwest Florida | Fort Myers, Florida, United States | — |
| JEM Research Institute | Lake Worth, Florida, United States | — |
| Premiere Research Institute of Palm Beach, Neurology | Palm Beach, Florida, United States | — |
| Brain Matters Research | Stuart, Florida, United States | — |
| Indiana University School of Medicine | Indianapolis, Indiana, United States | — |
| University of Kansas Medical Center | Fairway, Kansas, United States | — |
| Neurological Associates of Albany | Albany, New York, United States | — |
| Dent Neurological Associates | Amherst, New York, United States | — |
| Columbia University Irving Medical Center | New York, New York, United States | — |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04381468